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ABSTRACT Cell cultures prepared from fetal niurine
liver were infected by Abelson murine leukemia virus.
After about 2 weeks, proliferating cells of lymphoid mor-
phology appeared in some of the cultures. Addition of 2-
mercaptoethanol to the initial culture medium greatly
enhanced the appearance of the lymphoid cells. Immuno-
globulin determinants were evident on the cells in some
cultures. Continuous passage of the cells in certain cul-
tures was possible and the passaged cells could form
tumors after animal inoculation. Because Abelson murine
leukemia virus is able to induce in vitro malignant trans-
formation of lymphoid cells, it probably causes leukemia
by directly affecting cellular growth control.
The type-C RNA tumor viruses cause leukemia in a large
number of species, yet the mechanism of leukemogenesis has
remained unclear partly for lack of in vitro transformation
systems for hematopoietic cells. Several isolates of murine
leukemia virus, typified by the Moloney leukemia virus (M-
MuLV) and Gross virus, cause tumors of lymphoid tissues
originating in the thymus after a latent period of 3-6 months
(1). These viruses replicate in vitro but do not transform the
infected cells or cause alteration in cellular growth control.
Abelson and Rabstein (2) isolated an RNA tumor virus,
Abelson leukemia virus (A-MuLV), which, in association with
M-MuLV, causes a rapidly progressive lymphosarcoma or
leukemia that does not involve the thymus. The tumor cells
all lack 0 antigen (3), an antigen found on M-MuLV-induced
tumors (4). Some of the A-MuLV-induced tumors are prob-
ably of bone marrow-derived (B-cell) origin because they have
immunoglobulin (Ig) on their surface (3). The majority of the
cells, however, have neither Ig nor the C3 complement recep-
tor of B-cells (3) and may represent a population of malignant
null cells.
Scher and Siegler (5) have shown that A-MuLV directly
transforms NIH/3T3 cells in vitro. A-MuLV was shown to be
defective for replication and to require a helper virus, such
as M-MuLV, in order to replicate (5).
Since A-MuLV has a transforming activity for 3T3 cells
and causes the rapid appearance of lymphoid tumors in vivo,
this agent was used to study the effect of a leukemia virus on
hematopoietic cells. Murine fetal liver contains a population
of cells able to restore complete hematopoietic function to
lethally-irradiated allogeneic recipients (6) and, therefore,
represents a rich source of hematopoietic stem cells. We now
show that A-MuLV infection of fetal liver cell cultures induces
rapid proliferation of lymphoid cells some of which have Ig
determinants on their surface. These cells can be subcultured
in vitro and induce tumors in animals.
MATERIALS AND METHODS
Cells and Culture Methods. Cell cultures were prepared from
the livers of embryos from 12- to 16-day pregnant Swiss or
Balb/c mice. Livers from the embryos of one mother were
pooled for each experiment. The livers were shredded using
a stainless steel mesh and the cells were suspended in medium
containing RPMI-1640 and 20% fetal calf serum (Irvine
Scientific Co.) that had been heat inactivated at 560 for 30
min. Antibiotics were not used. In some experiments, 2-mer-
captoethanol (Aldrich Chemical Co.) was added to a final
concentration of 50 ,uM. About 7.5 X 105 nucleated cells were
plated in 30 mm plastic petri plates (Nunc) in 1.5 ml of
medium.
The cultures were maintained at 370 in a humidified 5%
CO2 atmosphere. They were fed weekly by the addition of 1
ml of medium. When medium completely filled the dish,
spent medium was centrifuged to retain any cells that might
be in the medium and the cells were returned to the cultures.
Infection of Cell Cultures. A-MuLV was prepared from a
cloned NIH/3T3 nonproducer cell line (ANN-1) (5) infected
with clonal M-MuLV (7). A-MuLV virus preparations had
titers of 5 X 103 to 5 X 104 focus-forming units/ml by the
NIH/3T3 transformation assay (5) and a titer of 1 to 2 X
106 plaque-forming units by the XC plaque assay with NIH/
3T3 cells (8). These preparations induce Abelson leukemia in
animals (unpublished data). For treating mock-infected con-
trol cultures, conditioned medium was harvested from rapidly
growing cultures of an A-MuLV transformed-nonproducer cell
line (ANN-1) (5). Clonal M-MuLV, grown on NIH/3T3
cells, had a titer of 1 to 5 X 106 plaque-forming units/ml after
dilution in ANN-1 medium. These virus preparations induced
thymic lymphoma in mice (unpublished data). Both virus
preparations and the conditioned medium were filtered
through 0.45 /m Millipore filters prior to use. Cells cultures
were infected 1-4 hr after plating with 0.5 ml of A-MuLV
stock, MI-MNuLV, or treated with 0.5 ml of conditioned
medium.
Detection of Surface Immunoglobulin. The presence of Ig on
the surface of transformed cells was detected by direct
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Abbreviations: MI-MuLV, Moloney leukemia virus; A-MuLV,
Abelson leukemia virus; B-cell, bone marrow-derived lympho-
cyte Ig, immunog]obulin.
Proc. Nat. Acad. Sci. USA 72 (1975)
TABLE 1. Transformation of hematopoietic cells by A-MuLV
Virus replication
Transformed cultures Nontransformed cultures
Cellular A-MuLV M-MuLV A-MuLV M-MuLV
transformation (FFU/ml) (PFU/ml) (FFU/ml) (PFU/ml)
A-MuLV Yes 1-5 X 103 5-10 X 105 <101 5-10 X 103
M-MuLV No - 0 5-10 X 103
Conditioned medium No 0 0
Supernatants of all cultures were removed 3 weeks post infection and tested for the presence of focus-forming virus (A-MuLV) and
plaque-forming virus (M-MuLV) using the NIH/3T3 transformation assay and the XC plaque assay.
FFU, focus-forming units; PFU, plaque-forming units.
immunofluorescent staining. Cells proliferating in the medium
of transformed cultures were centrifuged and 5 X 106 cells
were suspended in 0.2 ml of Dulbecco's modified Eagle's
medium supplemented with 2% heat inactivated fetal calf
serum. Fluorescein-conjugated anti-mouse Ig (0.1 ml) was
added and the cells were incubated on ice for 20 min. The
cells were centrifuged, washed in a 100-fold excess of phos-
phate buffered saline and mounted for microscopic examina-
tion. For all experiments, control spleen and thymus cell
suspensions from freshly sacrificed mice were included. In all
cases, thymus cell suspensions contained no cells which re-
acted with the fluorescein-conjugated antibody. Spleen suspen-
sions contained 35-50% Ig positive cells.
Fluorescein-conjugated anti-mouse Ig was obtained from
three sources. An equal mixture of anti-IgA, -IgM, and -IgG
(Meloy Laboratories) was used in most experiments. Two
preparations of anti-mouse Ig prepared from ammonium
sulphate precipitation of whole mouse serum (Progressive
Laboratories and Dr. E. Unanue, Harvard Medical School)
were used in several experiments. All preparations gave com-
parable results.
Tumor Induction. Adult Balb/c mice were injected intra-
peritoneally with 0.5 ml of Balb/c lymphoid cells that had
been transformed by A-MuLV and passaged with mercapto-
ethanol. Some mice received a priming injection of either 0.5 or
1 ml of pristane (2,6,10,14-tetramethylpentadecane) (Aldrich
Chemical Co.) intraperitoneally 1-3 weeks prior to the injec-
tion of the cells. Moribund animals were sacrificed and
autopsied. Smears of ascitic fluid and touch preps of tumors
were made and stained with Wright-Giemsa. In addition,
tumors were fixed and prepared for histology (9).
RESULTS
Transformation of Fetal Liver Cells. Murine fetal liver cells
from Balb/c or Swiss mice were infected with A-MuLV which
was rescued from the nonproducer cell line ANN-1 by M-
MuLV. Mock-infected cultures were treated with medium
conditioned by growth of the non-producer cell line. Parallel
cultures were infected by M-MuLV alone. M-MuLV was
diluted 1:10 in ANN-1 conditioned medium because cultures
plated in the absence of conditioned medium showed poor
survival.
Cultures infected with A-MuLV were sacrificed at intervals
post-infection and the morphology of the cells in the mono-
layer and medium was examined after Wright-Giemsa stain-
ing. Twenty-four to 48 hr after plating, monolayers composed
of epithelioid and fibroblastic cells had been formed. A sig-
nificant number of cells with the morphologic characteristics
of macrophages was also seen. Twenty-four to 72 hr after
plating, cells of the erythroid series were the predominant
nonadherent cell type. After 4-6 days, nautrophilic granulo-
cytes became the predominant nonadherent cell type. These
granulocytes were present until 10-14 days post-infection.
Dense areas of small round cells were noted in a few of the
A-MuLV-infected cultures 10-15 days post-infection. In
such cultures, nonadherent cells proliferated rapidly, be-
coming the predominant cell type in the culture and reach-
ing a density of 3 to 5 X 106 cells per ml in 5-7 days. For the
purposes of discussion we will refer to the process of generating
these cells as "transformation" and to the cells as "trans-
formed" cells.
In cultures injected with M-MuLV alone or mock-infected,
development of cell types followed the same pattern as in the
A-MuLV-infected cultures for the first 10 days. Thereafter,
no evidence of transformed cells was ever found. The granulo-
cytic cells disappeared by day 14 leaving adherent fibroblastic
and epithelioid cells which could be maintained for 3 months
or more.
Media from all cultures were assayed for the presence of
infectious virus. A-MuLV-infected cultures replicated both
A-MuLV and M-MuLV (Table 1). Cultures containing the
transformed non-adherent cells produced much higher titers
of both A-MuLV and M-MuLV than A-MuLV-infected
cultures that were not transformed. M-MuLV-infected cul-
tures replicated M-MuLV with an efficiency comparable to
the M-MuLV component in A-MuLV-infected cultures which
did not transform.
Cell cultures from Balb/c and Swiss mice transformed with
equal efficiency.
Morphology of Transformed Cells. Cells transformed by
A-MuLV had the appearance of lymphoblasts when examined
by light microscopy (Fig. 1). The majority of these cells had
a relatively large nucleus with a poorly defined nucleolus. The
small rim of cytoplasm contained no granules but vacuoles
were often noted. The leukocyte peroxidase reaction, used to
identify cells of the myeloid series, was consistently negative.
These in vitro transformed cells resembled closely the ascites
form of tumors induced in vivo by A-MuLV.
To confirm the lymphoid nature of these cells, a representa-
tive transformed culture was fixed and processed for electron
microscopy (10) at 2.5 weeks after infection. Approximately
95% of the cells had lymphoid characteristics (Fig. 2) whereas
5% had the appearance of macrophages. The lymphoid cells
had a relatively large nucleus with scanty cytoplasm. The
1-jeukemogenesis In Vitro 1933
1934 Cell Biology: Rosenberg et al.
Al.
FIG. 1. Transformed cells stained with Wright-Giemsa. These cells have the characteristic appearance of lymphoblasts (X 1000).
chromatin was of a fine pattern and an ill-defined nucleolus
was often evident. The cytoplasm contained many free
ribosomes and little rough endoplasmic reticulum. No phago-
cytic vacuoles, lysosomes, or glycogen granules were noted.
Enhancement of Transformation. Under the culture condi-
tions used above, A-MuLV was able to transform lymphoid
cells in only 3-4% of the infected cultures. To attempt to
increase the frequency of transformation, we added 2-mer-
captoethanol to the culture medium because this reducing
agent has been shown to enhance the viability of normal
lymphocytes in vitro (11) and is a requirement for the culture
of some lymphoid tumor cells (12, 13). From 70-100% of A-
MuLV infected cultures grown in medium containing 50 ,uM
mercaptoethanol become transformed (Table 2). Transformed
cells were not detected in the M-MuLV-infected or mock-
infected mercaptoethanol-treated cultures in any experiments.
Although the frequency of cellular transformation was
enhanced by the addition of mercaptoethanol, mercapto-
ethanol did not affect the latent period for the transformation
event. The initial rate of lymphoid cell proliferation in mer-
captoethanol-treated and untreated cultures was also approxi-
mately equal with the cells reaching densities of 3 to 5 X 106
cells per ml 5-7 days after transformation was first noted.
TABLE 2. Effect of mercaptoethanol on transformation of
lymphoid cells
Frequency of transformation*
With Without
mercaptoethanol mercaptoethanol
A-MuLV 21/30 1/30
M-MuLV 0/15 0/15
Conditioned medium 0/15 0/15
* Number of cultures with transformed lymphoid cells/total
cultures infected.
The ability of the transformed lymphoid cells to proliferate
after subculture, however, depended upon the presence of
mercaptoethanol. Cells from mercaptoethanol-treated cultures
were harvested after achieving a density of 3 to 5 X 106 cells
per ml and were routinely passaged every 3-4 days by trans-
ferring 5 to 10 X 104 cells per ml into 10 cm plates. An
approximately 10-fold growth of cells occurred between
passages. Cells from cultures grown without mercaptoethanol
could be passaged only after maintenance at high density for
long periods of time (up to 2 months). While every mercapto-
ethanol-treated culture tested could be readily subcultured,
only 1 of 9 untreated cultures produced cells which could be
passaged. Passaged cultures from either source are relatively
homogeneous, with lymphoblasts proliferating in the culture
medium and no adherent cells.
In a significant proportion (up to 50%) of the A-MuLV-
infected untreated fetal liver cells, a second, nonlymphoid
cell was noted 3-4 weeks after infection. These cells appeared
in mercaptoethanol-treated cultures infrequently but never
appeared in M-MuLV-infected or mock-infected cultures.
They were larger than lymphoid cells and had many fine
basophilic cytoplasmic granules. Their nucleus was occa-
sionally acentric with a sharply defined nucleolus. These cells,
which resemble mast cells, may represent a second class of
A-MuLV transformants.
TABLE 3. Presence oj immunoglobulin on A-MuLV-
transformed lymphoid cells
Frequency of % Cells positive
Source of immunoglobulin in positive
lymphoid cells positive cultures* cultures
Transformed culture
- mercaptoethanol 4/6 60-90
Transformed culture
+ mercaptoethanol 2/11 60-70
* Number of cultures with positive cells/total cultures tested.
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FIG. 2. Electron micrograph of a transformed cell. Cells were fixed in 2.5% glutaraldehyde and post-fixed in 1.3% osmium tetroxide
(10) (X22,000).
Immunoglobulin on the Surface of Transformed Cells. The
A-MuLV transformed lymphoid cells were screened for the
presence of surface Ig, a characteristic of B-cells. A high
percentage of the transformed fetal liver cultures grown in
the absence of mercaptoethanol had cells present in the
medium with Ig determinants on their surface (Table 3). In
such positive cultures, 60-90% of the cells had Ig. Only 20%
of the cultures grown in the presence of mercaptoethanol had
surface Ig. As in cultures not treated with mercaptoethanol,
60-70% of the cells in the positive cultures had Ig determi-
nants. Thus, B-cells were initially present in these trans-
formed cultures. Two pools of passaged cells lacked detectable
surface Ig at one month after initial subculture. Cytotoxicity
assay (14) of one of these pools, derived from a transformed
Balb/c fetal liver culture demonstrated that these cells also
lacked the 0 antigen characteristic of thymus-derived lympho-
cytes (T-cells) (4). These cells had the H-2d histocompatibility
antigen found in Balb/c mice. This mass culture of A-MuLV
transformants may be a population of null cells.
Tumor Induction by the Transformed Lymphoid Cells.
Transformed lymphoid cells isolated from Balb/c fetal liver
and subsequently passaged in vitro were injected intraperi-
toneally into adult Balb/c mice to assay for tumorigenicity.
Because pristane has been shown to enhance passage of pri-
mary Abelson tumors in Balb/c mice (3), some mice received
a priming injection of 0.5 or 1 ml of pristane 1-3 weeks prior
to the injection of the A-MuLV-transformed cells. Solid
tumors and ascites developed in all of the mice within 24 days
of cell inoculation (Table 4).
TABLE 4. Tumorigenicity of A-MuLV transformed
lymphoid cells
Mean latent Frequency of
period (days) tumors*
Inoculum Pristane- Pristane-
(cells/mouse) primed Unprimed primed Unprimed
10 X 106 10 11 9/9 7/7
1 X 106 12 18 4/4 14/14
* Number of animals with tumor/number of animals examined.
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Histologic examination of the tumors showed that they
were composed of lymphoblasts infiltrating connective tissue,
muscle, fat, and pancreatic tissue. The mitotic index in these
rapidly growing tumors was approximately 1.6%. The ascites
fluid also contained many lymphoblasts. No significant differ-
ence was noted in the frequency or latent period of tumor
development between pristane-primed and unprimed mice.
The solid tumor masses, however, were larger in pristane-
primed animals. Both the solid tumors and ascites cells were
morphologically indistinguishable from A-MuLV-induced
tumors passaged in vivo. The tumors appear to be of donor
origin because virus-induced tumors do not arise before the
sixth week in adult mice (2), and A-MuLV does not cause
ascites in unprimed mice (15).
DISCUSSION
A-AIuLV infection of fetal liver is able to induce the con-
tinuous growth of populations of lymphoid cells. These
lymphoblastoid cells have been maintained in culture for
more than 30 generations, and are malignant because they
cause rapidly growing invasive tumors. We consider these
properties to define an in vitro transformation event induced
by A-MuLV. Transformation of lymphoid cells in vitro by
A-MuLV demonstrates that this virus can act directly to alter
the growth properties of lymphoid cells and therefore probably
causes leukemia by directly interfering with normal growth
and differentiation.
The A-MuLV stock used in these experiments was a mixture
of A-MNuLV and M-MuLV. No transformation was demon-
strable by M-MuLV alone nor was transformation demon-
strated in cultures treated with medium that had been condi-
tioned by A-MuLV transformed nonproducer cells (ANN-1).
Thus, the A-MuLV component rescued from ANN-1 cells
appears to be responsible for the lymphoid cell transformation.
iMercaptoethanol increases the transformation frequency of
A-MuLV-infected cultures. This reducing agent may act
either by increasing the number of viable cells susceptible to
transformation or may allow more transformed cells to repli-
cate and become evident. We do not know if transformed
cells appearing in mercaptoethanol-treated cultures are func-
tionally different from those in untreated cultures.
The presence of Ig on the surface of some transformed cells
indicates that these cells are of B-cell origin and further
supports the finding that the A-MuLV can cause B-cell
tumors (3). M\ost A-MuLV tumors lack Ig, C3 receptor, and
a antigen indicating that they are malignant null cells. Some
of our A-MuLV-transformed cells are also similar to null cells
because they lack Ig determinants and 0 antigen.
In vitro stimulation of hematopoietic cell growth has been
achieved in other systems although complete transformation
to malignant cells has not been previously reported. Avian
myeloblastosis virus has been shown to transform myeloid
cells from chick embryo (16, 17). As with the A-MuLV com-
plex, this virus is probably a mixture of defective transforming
virus and helper (18). Although avian myeloblastosis virus
alters the growth of myeloid cells in vitro, these cells do not
form tumors in animals (19). The Epstein-Barr virus allows
the establishment of permanent lines of human or primate
lymphoid cells (20, 21). The tumorigenicity of these cells has
not been conclusively established (22).
Sklar et al. (23) have previously infected short-term (4-6
days) cultures of mouse splenocytes with A-MuLV. After
inoculation into animals, the cultured cells developed into
lymphoblastic tumor cells. Their system differs from ours in
that cells from pristane-primed adult animals were infected
and animal inoculation was required for transformation to be
recognized.
The work presented here demonstrates that A-MuLV
causes lymphoid cells to undergo a malignant transformation
in vitro. The early events in lymphoid cell transformation by
leukemia virus can now be studied under controlled conditions.
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